Iptacopan is a small-molecule inhibitor targeting complement factor B, showing positive therapeutic effects in the treatment of PNH, C3 glomerulonephritis, and other diseases. This evidence concerns the gene CFB and paroxysmal nocturnal hemoglobinuria.